Stay updated on BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial
Sign up to get notified when there's something new on the BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial page.

Latest updates to the BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial page
- CheckyesterdayChange DetectedDifference0.2%
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has removed detailed information about a clinical study comparing BCD-020 and MabThera for treating non-Hodgkin lymphoma, while adding a new version number and a reference to Follicular Non-Hodgkin's Lymphoma.SummaryDifference25%
- Check31 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check38 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check74 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial page.